The terms, per the grant. On March 25, 2025, Amgen was issued US12258404B2, "Bispecific antibody construct directed to MUC17 and CD3." The CPC tags — C07K 16/2809 (anti-CD3), C07K 16/3092 (the tumor-antigen binder), plus the C07K 2317 engineering series — describe a dual-targeting construct that bridges a T cell to a tumor cell.
Why bispecific IP anchors deals: a T-cell engager is an engineered construct that physically links a cytotoxic T cell to a tumor antigen, redirecting the immune system without ex-vivo cell manufacturing. The specific binder pairing and construct format are protectable, and demonstrated activity has made this class a focus of large oncology partnerships.
The structure point: a bispecific deal is priced on the construct and its target pairing. For a model, the tumor-antigen binder defines the addressable indication, while the CD3-engagement format can be reused across targets. Naming the grant shows which binders and format a deal actually controls.
What the grant does not promise: a clinical result, an approval, or freedom from competing bispecific and binder estates. It is an exclusivity claim on a specific dual-targeting construct within a crowded engager field.
The takeaway: when a bispecific deal crosses the desk, read the construct, the tumor-antigen binder, and the CD3 format as the load-bearing assets. Amgen's March 2025 MUC17xCD3 grant is a dated, concrete example of the engager IP behind oncology dealmaking.